Autoantibody profiling for the study and treatment of autoimmune disease

doi:10.1186/ar426

Arthritis Res

Volume 4
Issue 5

Viewing options:

Abstract
Full text
PDF (112KB)

Associated material:

Related literature:

Articles citing this article
on BioMed Central
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Hueber W
Utz PJ
Steinman L
Robinson WH

on PubMed

Hueber W
Utz PJ
Steinman L
Robinson WH
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Review

Autoantibody profiling for the study and treatment of autoimmune disease

Wolfgang Hueber¹, Paul J Utz¹^,3, Lawrence Steinman²^,3 and William H Robinson¹^,2^,3

¹Department of Medicine, Division of Rheumatology and Immunology, Stanford University School of Medicine, Stanford, California, USA

²Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA

³Tolerion, Palo Alto, California, USA

author email corresponding author email

Arthritis Res 2002, 4:290-295doi:10.1186/ar426


Published:	7 May 2002

Abstract

Proteomics technologies enable profiling of autoantibody responses using biological fluids derived from patients with autoimmune disease. They provide a powerful tool to characterize autoreactive B-cell responses in diseases including rheumatoid arthritis, multiple sclerosis, autoimmune diabetes, and systemic lupus erythematosus. Autoantibody profiling may serve purposes including classification of individual patients and subsets of patients based on their 'autoantibody fingerprint', examination of epitope spreading and antibody isotype usage, discovery and characterization of candidate autoantigens, and tailoring antigen-specific therapy. In the coming decades, proteomics technologies will broaden our understanding of the underlying mechanisms of and will further our ability to diagnose, prognosticate and treat autoimmune disease.